vs
Side-by-side financial comparison of ALUMIS INC. (ALMS) and AWARE INC (AWRE). Click either name above to swap in a different company.
AWARE INC is the larger business by last-quarter revenue ($3.4M vs $2.7M, roughly 1.3× ALUMIS INC.).
ALUMIS INC. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for patients suffering from autoimmune and inflammatory disorders. It advances multiple product candidates through clinical trials, aiming to address unmet medical needs for patient populations across global markets.
AWARE Inc. is a technology firm specializing in biometric software and identity verification solutions. It develops fingerprint, facial, and iris recognition tools, serving government agencies, financial institutions, and enterprise clients primarily across North America and global regulated markets.
ALMS vs AWRE — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.7M | $3.4M |
| Net Profit | $59.3M | — |
| Gross Margin | — | 90.1% |
| Operating Margin | -5271.5% | -107.8% |
| Net Margin | 2225.1% | — |
| Revenue YoY | — | -6.2% |
| Net Profit YoY | 205.0% | — |
| EPS (diluted) | $0.77 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $3.4M | ||
| Q4 25 | — | $4.7M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $2.7M | $3.9M | ||
| Q1 25 | $17.4M | $3.6M | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | — | $3.8M | ||
| Q2 24 | — | $4.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $59.3M | $-1.8M | ||
| Q1 25 | $-99.0M | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.1M |
| Q1 26 | — | 90.1% | ||
| Q4 25 | — | 94.7% | ||
| Q3 25 | — | 90.4% | ||
| Q2 25 | — | 91.3% | ||
| Q1 25 | — | 93.2% | ||
| Q4 24 | — | 99.6% | ||
| Q3 24 | — | 93.0% | ||
| Q2 24 | — | 93.8% |
| Q1 26 | — | -107.8% | ||
| Q4 25 | — | -31.1% | ||
| Q3 25 | — | -25.2% | ||
| Q2 25 | -5271.5% | -50.3% | ||
| Q1 25 | -583.9% | -51.3% | ||
| Q4 24 | — | -30.7% | ||
| Q3 24 | — | -38.1% | ||
| Q2 24 | — | -31.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | -31.2% | ||
| Q3 25 | — | -20.5% | ||
| Q2 25 | 2225.1% | -45.4% | ||
| Q1 25 | -569.1% | -44.3% | ||
| Q4 24 | — | -24.8% | ||
| Q3 24 | — | -30.3% | ||
| Q2 24 | — | -25.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | $0.77 | $-0.08 | ||
| Q1 25 | $-1.82 | $-0.08 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $486.3M | $4.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $485.3M | — |
| Total Assets | $610.9M | $33.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.6M | ||
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $6.3M | ||
| Q2 25 | $486.3M | $7.3M | ||
| Q1 25 | $208.7M | $8.5M | ||
| Q4 24 | — | $13.0M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $11.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $26.1M | ||
| Q3 25 | — | $27.2M | ||
| Q2 25 | $485.3M | $28.1M | ||
| Q1 25 | $168.3M | $29.5M | ||
| Q4 24 | — | $30.9M | ||
| Q3 24 | — | $31.9M | ||
| Q2 24 | — | $32.6M |
| Q1 26 | — | $33.2M | ||
| Q4 25 | — | $37.2M | ||
| Q3 25 | — | $40.3M | ||
| Q2 25 | $610.9M | $38.1M | ||
| Q1 25 | $261.3M | $39.9M | ||
| Q4 24 | — | $42.6M | ||
| Q3 24 | — | $43.7M | ||
| Q2 24 | — | $43.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-106.4M | — |
| Free Cash FlowOCF − Capex | $-107.0M | — |
| FCF MarginFCF / Revenue | -4012.3% | — |
| Capex IntensityCapex / Revenue | 23.1% | — |
| Cash ConversionOCF / Net Profit | -1.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0M | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | $-106.4M | $-1.2M | ||
| Q1 25 | $-80.4M | $-2.9M | ||
| Q4 24 | — | $683.0K | ||
| Q3 24 | — | $-765.0K | ||
| Q2 24 | — | $-668.0K |
| Q1 26 | — | — | ||
| Q4 25 | — | $926.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | $-107.0M | — | ||
| Q1 25 | $-80.4M | $-3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | -4012.3% | — | ||
| Q1 25 | -462.3% | -82.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 23.1% | 0.0% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.79× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
